Rob de Ree

Rob de Ree is an Operating Partner at BioGeneration Ventures and the Chief Executive Officer of NorthSea Therapeutics. Previously, he served as the CEO of Dezima Pharma, which was acquired by Amgen in 2015, and as the CEO of BMEYE, which was sold to Edwards Lifesciences in 2012. His earlier career includes sales and marketing roles at Medtronic and licensing leadership at Crucell, following a Master of Science in pharmacy from the University of Groningen. In addition to his executive positions, he acts as Chairman of the Supervisory Board at Ventinova Medical, serves on the board of Mellon Medical, and makes angel investments ranging from $100,000 to $1 million per deal. His current professional focus centers on scaling life sciences, biotechnology, and medical device startups through operational support and strategic board leadership toward successful exits.